anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a pharmaceutical composition, and a preparation method, preparation and application thereof. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 200-400 parts of Yushu, 800-1200 parts of Tinospora crispa, 800-1200 parts of belamcanda rhizome, 100-300 parts of pepper, 200-400 parts of dried ginger, 200-600 parts of brazilwood, 100-300 parts of safflower and 100-300 parts of Eleutherine plicata Herb. The preparation method comprises the following steps: respectively extracting, concentrating and drying to obtain the pharmaceutical composition. Pharmaceutically acceptable adjuvants can be added into the pharmaceutical composition to prepare powder, tablets, capsules, granules, dripping pills or honeyed pills. The invention also discloses application of the pharmaceutical composition in preparation of medicines for treating injuries from falls. The Yushu used as the main medicine has the effects of tonifying fire to strengthen the body, eliminating wind, promoting blood circulation, alleviating pain, promoting the subsidence of swelling and dissipating blood stasis; the dried ginger and pepper used as adjuvants can assist the main medicine to enhance the curative effect; the brazilwood has the effects of activating blood circulation to dissipate blood stasis and alleviating pain; the safflower has the effects of promoting blood circulation and dissipating blood stasis; the Eleutherine plicata Herb has the effects of promoting blood circulation, restoring menstrual flow, promoting the subsidence of swelling and removing toxicity; and the Tinospora crispa and belamcanda rhizome have the effects of replenishing water, moistening, replenishing essence and tonifying the marrow. All the components in the formula are combined for treating injuries from falls.
The invention provides an oral liquid contains Stichopus japonicus liquid, Syngnathus liquid, and herbal liquid. The Stichopus japonicus liquid is obtained by decocting fresh or dried Stichopus japonicus, digesting with enzymes, filtering and concentrating. The Syngnathus liquid is obtained by boiling Syngnathus together with Angelica sinensis, Ligusticum chuanxiong, Astragalus membranaceus, Cinnamomum cassia bark and Radix Glycyrrhizae; filtering; and concentrating. The herbal liquid is obtained by boiling Lycium barbarum fruit, Ziziphus jujuba and Crataegus pinnatifida; filtering and concentrating. The oral liquid has immunity enhancing, anti-fatigue, antiaging and anticancer effects. It is effective in ameliorating myocardial infarction and cerebral thrombosis; preventing cardiovascular and cerebrovascular diseases (such as hypertension), cancer and AIDS; and treating sexual impotence, spermatorrhea, traumatic injury, carbuncle and furuncle. It can be served as both pharmaceuticals and functional food.
PURPOSE:To obtain an antimicrobial amorphous aluminosilicate exhibiting antimicrobial activity against various bacteria and fungi, by substituting the total or a part of ion-exchangeable ion in an amorphous aluminosilicate with an antimicrobial metallic ion and NH4<+>. CONSTITUTION:An amorphous aluminosilicate(AAS) expressed by general compositional formula xM2O.Al2O3.ySiO2.zH2O (M is generally an alkali metal element such as Na or K; x, y and z are molar ratios of the metal oxide, silica and water of crystallization, respectively) is prepared beforehand. The AAS is suspended e.g., in water and the obtained slurry of AAS is made to contact with an aqueous solution containing an antimicrobial metallic ion and NH4<+>. The ion-exchangeable ion in the AAS is substituted with the above ions by this process. The contact treatment is carried out preferably at 40-60 deg.C for 10-24hr. The antimicrobial ion is e.g., ion of silver, copper or zinc. The antimicrobial amorphous aluminosilicate produced by this process can be added to a resin without causing the discoloration of the resin with time and exhibits excellent antimicrobial property comparable to conventional antimicrobial AAS.
We will study ten volunteers, each one on three occasions. Each volunteer will receive only crystalloid one time, only colloid another time, and on the third occasion first a colloid and then a crystalloid one hour later. The different protocols will be in random order in the different volunteers. During all these tests we will sample the hemoglobin (both invasive and non-invasive) every fifth minute in the beginning (every tenth minute later) after the infusion. On six to nine occasions during each test we will analyse Albumin, Cystatin-C, Ig-G, Ig-M as markers of hemodilution and D-Dimer, Fibrinogen, Factor VII, PK-INR (prothrombin complex international normalized ratio), and aPTT (activated partial thromboplastin time) as markers of coagulation. The volunteers are also monitored regarding non-invasive blood pressure and pulse rate.
Protein tyrosine phosphatases (PTPs) are the class of dephosphorylation enzymes that catalyze the removal of phosphate groups from tyrosine residues on proteins responsible for various cellular processes. Any disbalance in signal pathways mediated by PTPs leads to various disease conditions like diabetes, obesity, cancers, and autoimmune disorders. Amongst the PTP superfamily, PTP1B, SHP2, Cdc25, and LMW-PTP have been prioritized as druggable targets for developing medicinal agents. PTP1B is an intracellular PTP enzyme that downregulates insulin and leptin signaling pathways and is involved in insulin resistance and glucose homeostasis. SHP2 is involved in the RAS-MAPK pathway and T cell immunity. Cdk-cyclin complex activation occurs by Cdc25-PTPs involved in cell cycle regulation. LMW-PTPs are involved in PDGF/PDGFR, Eph/ephrin, and insulin signaling pathways, resulting in certain diseases like diabetes mellitus, obesity, and cancer. The signaling cascades of PTP1B, SHP2, Cdc25, and LMW-PTPs have been described to rationalize their medicinal importance in the pathophysiology of diabetes, obesity, and cancer. Their binding sites have been explored to overcome the hurdles in discovering target selective molecules with optimum potency. Recent developments in the synthetic molecules bearing heterocyclic moieties against these targets have been explored to gain insight into structural features. The elaborated SAR investigation revealed the effect of substituents on the potency and target selectivity, which can be implicated in the further discovery of newer medicinal agents targeting the druggable members of the PTP superfamily.
PURPOSE:To obtain the sterilizable subject preventive capable of effectively preventing the crisis of avian coccidiosis and having excellent safety and handleability by using an active component consisting of an antibody having specificity to sporozoite of coccidium sensitive to chicken and obtained from an animal other than chicken. CONSTITUTION:Oocyst is separated from the feces, intestinal wall or content of intestine of chicken infected with avian coccidiosis. The skin of the oocyst is ground to obtain sporozoite. Preferably after purifying the sporozoite, the sporozoite or its disintegrated product is inoculated to an animal other than chicken (preferably rabbit) and the objective antibody is separated from the body fluid (preferably blood) of the sensitized animal. The preventive is administered at a rate of 10 to 500mul/body as antiserum and 0.01 to 100mug/body as gamma-globulin fraction. The administration period is arbitrary from new-born chicken to grown bird.
Hypercalciuria is a common clinical pediatric problem that in some children is associated with renal stones. Most renal stones (80%) are formed by calcium oxalate, calcium phosphate phases (apatite), and brushite (calcium monohydrogen phosphate). Hypercalciuria can be either primary (accounts for the vast majority of children with calcium stones) or secondary. Treatment for children with calcium stones involves non-pharmacological and pharmacological interventions. Non-pharmacological interventions include high fluid intake, low sodium, and potassium enhanced diet, with RDA calcium and protein. Historically, the specific treatment for hypercalciuric stone formers has included thiazides, which reduce calciuria, lower the urinary saturation of calcium oxalate and phosphate, and restore normal intestinal calcium absorption. However thiazides induce hypokalemia and hypocitraturia, and the latter attenuates the beneficial effects of the drug on stone formation. Currently, the drug of choice replacing thiazides in treating idiopathic hypercalciuria is potassium citrate. Potassium citrate is readily absorbed from the gastrointestinal tract, and after being excreted in the urine, it inhibits the crystallization of stone forming calcium salts by binding the calcium ion, thus decreasing its urinary saturation and inhibiting the nucleation and crystal growth of calcium oxalate; therefore, potassium citrate is an effective stone inhibitor agent. A major advantage of potassium citrate is its lack of side effects. One of the problems seen in clinical practice is that some children with primary hypercalciuria, even after the calciuria is treated successfully with potassium citrate, continue to develop stones. It has been suggested that an elevation in urine pH, seen in some patients treated with potassium citrate, may result in an alkaline urinary milieu which promotes calcium phosphate stone formation. In this study, the researchers plan to investigate the effects of potassium citrate on urine chemistries and acid-base balance in children who are hypercalciuric stone formers. The researchers will try to identify whether the beneficial effects of potassium citrate supplementation on lowering urine calcium and increasing citrate might be offset by too high urine pH (\>8) which could promote the formation of calcium phosphate stones. Three groups of subjects aged 5-17 years will be studied: group 1 - idiopathic hypercalciuric stone formers; group 2 - idiopathic hypercalciuric non-stone formers; and group 3 - normocalciuric subjects. Three visits will be scheduled for each participant, and the subjects will receive two doses of potassium citrate. Urine chemistries and acid-base parameters will be measured. The researchers will try to learn whether it is the child's characteristics, the disease manifestations, the dose of the drug, or a combination of the above which may be the cause of the development of very alkaline urine. Based on the study results, the researchers hope to be able to better "tailor" the individual treatment for each child with kidney stones due to idiopathic hypercalciuria.
NEW MATERIAL:An adamantane platinum complex of formulaI{X and Y are halogen, nitrato, OH, sulfonato, lactic acid residue or group of formula II[(m) is an integer 1-6], or X and Y form a group of formula III (R is H, OH or lower alkyl), etc.}. EXAMPLE:Dichloro(1,2-diaminoadamantane)platinum (II). USE:Parenterally administered as an antitumor agent due to improved antitumor action with low toxicity thereof. PROCESS:1,2-Diaminoadamantane hydrochloride is reacted with an alkali metallic tetrahalogenoplatinate (II) having the halogen to be introduced in water to give the compound of formulaI(X and Y are halogen). The X and Y groups are then converted into the desired groups. For example, a compound of formulaI(X and Y are the same and halogen) is reacted with silver nitrate in water to give the compound of formulaI(X and Y are the same and nitrato).
Airway ultrasound (US) is an easily available, portable, radiation-free imaging modality for quick, non-invasive, dynamic evaluation of the airway without sedation. This is useful in children with stridor, which is an emergency due to upper airway obstruction requiring immediate management. Several causes of stridor including laryngomalacia, laryngeal cyst, subglottic hemangioma, vocal cord palsy, and lymphatic malformations can be evaluated accurately. Thin musculature and unossified cartilages in children provide a good acoustic window. Thus, airway US is valuable, but underutilized for the evaluation of children with stridor. In this case-based review, we describe the technique, indications, anatomy, and pathologies on airway US.
PURPOSE:To obtain a micro-capsule which has stable opacity even when using it in a water system and the strength of its film is large by a method wherein insoluble salt is precipitated by a reaction with cations or anions required in the micro-capsule film with the necessary anions or cations. CONSTITUTION:Colored oiliness core substance is dispersed to either liquid of the two of a hydrophilic cation colloid water solution or a hydrophilic anion water solution, the other colloidal solution is admixed, pH is adjusted, and a micro-capsule is manufactured by means of a complex coacervation method. In this case, a water solution, to which necessary anions or cations are added or which contains these ions, is dispersed to the capsule, these ions are reacted with cations, such as, Ca, etc. or anions, such as, phosphoric acid, etc., and insoluble salt, such as, calcium phosphate, etc. is precipitated so as to cover a capsule film and under a condition that the one part is buried in the film. Thus, the opaque micro-capsule which the colors of the core substance do not appear to the outside is obtained.
A method for producing starch granules suitable as an excipient for an orally disintegrating tablet. Fluidized bed granulation is performed by spraying a starch paste in small amounts while a ²-starch is being fluidized using an air-fluidized bed. Subsequently, fluidized bed drying is performed at a temperature equal to or higher than the gelatinization temperature of the ²-starch. This yields starch granules having a high degree of gelatinization in comparison with the amount of ±-starch adhered to the ²-starch by the spraying of the starch paste. These starch granules alone impart satisfactory oral disintegratability and breaking strength to the tablet. Accordingly, when used as an excipient during tableting of orally disintegrating tablets, other auxiliary excipients such as saccharides or crystalline cellulose need not be added.
Participants in the control group have up to 10 in-person visits with a physical therapist over 12-months - equivalent to the dose provided to the mHealth condition. Participants are instructed by the physical therapist to engage in walking and perform the same progressive resistance and stretching exercises (tailored to their needs and provided in written format) at the same frequency (5x/week) as participants in the mHealth condition. Participants in the control condition are instructed to gradually progress their exercise program and to increase the amount of walking over a 1-year period. No cognitive-behavioral approaches or mHealth technology will be provided.
OBJECTIVE: Maternal exposure during pregnancy is a strong determinant of offspring health outcomes. Such exposure induces changes in the offspring epigenome resulting in gene expression and functional changes. In this study, we investigated the effect of maternal Western hypercaloric diet (HCD) programming during the perinatal period on neuronal plasticity and cardiometabolic health in adult offspring.
METHODS: C57BL/6J dams were fed HCD for 1 month prior to mating with regular diet (RD) sires and kept on the same diet throughout pregnancy and lactation. At weaning, offspring were maintained on either HCD or RD for 3 months resulting in 4 treatment groups that underwent cardiometabolic assessments. DNA and RNA were extracted from the hypothalamus to perform whole genome methylation, mRNA, and miRNA sequencing followed by bioinformatic analyses.
RESULTS: Maternal programming resulted in male-specific hypertension and hyperglycemia, with both males and females showing increased sympathetic tone to the vasculature. Surprisingly, programmed male offspring fed HCD in adulthood exhibited lower glucose levels, less insulin resistance, and leptin levels compared to non-programmed HCD-fed male mice. Hypothalamic genes involved in inflammation and type 2 diabetes were targeted by differentially expressed miRNA, while genes involved in glial and astrocytic differentiation were differentially methylated in programmed male offspring. These data were supported by our findings of astrogliosis, microgliosis and increased microglial activation in programmed males in the paraventricular nucleus (PVN). Programming induced a protective effect in male mice fed HCD in adulthood, resulting in lower protein levels of hypothalamic TGFβ2, NF-κB2, NF-κBp65, Ser-pIRS1, and GLP1R compared to non-programmed HCD-fed males. Although TGFβ2 was upregulated in male mice exposed to HCD pre- or post-natally, only blockade of the brain TGFβ receptor in RD-HCD mice improved glucose tolerance and a trend to weight loss.
CONCLUSIONS: Our study shows that maternal HCD programs neuronal plasticity in the offspring and results in male-specific hypertension and hyperglycemia associated with hypothalamic inflammation in mechanisms and pathways distinct from post-natal HCD exposure. Together, our data unmask a compensatory role of HCD programming, likely via priming of metabolic pathways to handle excess nutrients in a more efficient way.
Gabapentin oral solution is supplied as an oral solution containing 250 mg/5 mL of gabapentin. The inactive ingredients for the oral solution are anise flavor, artificial strawberry flavor, glycerin, hydrochloric acid, purified water, sodium hydroxide and xylitol.

Gabapentin is described as 1-(aminomethyl) cyclohexaneacetic acid with a molecular formula of C9H17NO2 and a molecular weight of 171.24. The structural formula of gabapentin is:

Gabapentin is a white to off-white crystalline solid with a pKa1 of 3.7 and a pKa2 of 10.7. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is -1.25.
BACKGROUND: Spinal cord injury (SCI) is a debilitating illness in humans that causes permanent loss of movement or sensation. To treat SCI, exosomes, with their unique benefits, can circumvent limitations through direct stem cell transplantation. Therefore, we utilized Gelfoam encapsulated with exosomes derived from human umbilical cord mesenchymal stem cells (HucMSC-EX) in a rat SCI model.
METHODS: SCI model was established through hemisection surgery in T9 spinal cord of female Sprague-Dawley rats. Exosome-loaded Gelfoam was implanted into the lesion site. An in vivo uptake assay using labeled exosomes was conducted on day 3 post-implantation. Locomotor functions and gait analyses were assessed using Basso-Beattie-Bresnahan (BBB) locomotor rating scale and DigiGait Imaging System from weeks 1 to 8. Nociceptive responses were evaluated through von Frey filament and noxious radiant heat tests. The therapeutic effects and potential mechanisms were analyzed using Western blotting and immunofluorescence staining at week 8 post-SCI.
RESULTS: For the in vivo exosome uptake assay, we observed the uptake of labeled exosomes by NeuN+, Iba1+, GFAP+, and OLIG2+ cells around the injured area. Exosome treatment consistently increased the BBB score from 1 to 8 weeks compared with the Gelfoam-saline and SCI control groups. Additionally, exosome treatment significantly improved gait abnormalities including right-to-left hind paw contact area ratio, stance/stride, stride length, stride frequency, and swing duration, validating motor function recovery. Immunostaining and Western blotting revealed high expression of NF200, MBP, GAP43, synaptophysin, and PSD95 in exosome treatment group, indicating the promotion of nerve regeneration, remyelination, and synapse formation. Interestingly, exosome treatment reduced SCI-induced upregulation of GFAP and CSPG. Furthermore, levels of Bax, p75NTR, Iba1, and iNOS were reduced around the injured area, suggesting anti-inflammatory and anti-apoptotic effects. Moreover, exosome treatment alleviated SCI-induced pain behaviors and reduced pain-associated proteins (BDNF, TRPV1, and Cav3.2). Exosomal miRNA analysis revealed several promising therapeutic miRNAs. The cell culture study also confirmed the neurotrophic effect of HucMSCs-EX.
CONCLUSION: Implantation of HucMSCs-EX-encapsulated Gelfoam improves SCI-induced motor dysfunction and neuropathic pain, possibly through its capabilities in nerve regeneration, remyelination, anti-inflammation, and anti-apoptosis. Overall, exosomes could serve as a promising therapeutic alternative for SCI treatment.
209,997. Heilbron, M. April 14, 1923. Hair, removing superfluous. - A mixture of resin or its equivalent, boiled vegetable oil, and a wax, such as Carnauba wax, moulded in stick form, is used as a depilatory. The end of the stick is heated, pressed on to the hair, allowed to cool, and then suddenly removed, bringing the hair away with it. A small quantity of white wax is preferably added to the mixtures. Suitable proportions are, resin 65 per cent, Carnauba wax 20 per cent, boiled linseed oil 10 per cent, white wax or hard paraffin wax 5 per cent. The resin, Carnauba wax, and white wax are melted together, and the vegetable oil added while the mixture is cooling.
A similar pilot study has already been conducted in adults and is now being tried in children to gather preliminary data for a grant submission. No safety issues were found in the adult pilot study. This study will evaluate the effect of different doses of propanolol. The risks of this study involve the risks of three (3) blood draws and the risks of propanolol. In order to minimize the risks children with sickle cell disease and asthma will be excluded because asthma is a contraindication to the use of propanolol. In addition, patients will not be hypertensive or bradycardic.
PURPOSE: A pharmaceutical composition containing plant extract for preventing or treating cancer is provided to reduce aldo-keto reductase 1B10(AKR1B10). CONSTITUTION: A pharmaceutical composition for preventing or treating cancer contains Ligularia fischeri var. spiciformis Nakai extract as an active ingredient. The extract is prepared using water, alcohol of 1c-c4, or a mixture solvent thereof. The cancer is lung cancer, liver cancer, gastric cancer, colorectal cancer, bladder cancer, prostate cancer, breast cancer, or blood cancer. The composition additionally contains a pharmaceutically acceptable carrier. A nutraceutical food or feed additive for preventing or treating cancer contains the Ligularia fischeri var. spiciformis Nakai extract as an active ingredient.
This group comprises participants demonstrating signs of Coronary Microvascular Disease (CMD), defined by a coronary flow reserve (CFR) measurement of less than 2.5. Participants in this category are experiencing myocardial ischemia without significant blockages in their coronary arteries.
Impaired Liver Function 

Do not use Melodetta 24 Fe in women with acute viral hepatitis or severe (decompensated) cirrhosis of the liver [see Contraindications (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue Melodetta 24 Fe if jaundice develops. 

Liver Tumors 

Melodetta 24 Fe is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases per 100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. 

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (greater than 8 years) COC users. However, the attributable risk of liver cancers in COC users is less than one case per million users.